Dengue Vaccine Rollout in San Luis Begins Mid-January
San Luis to Roll Out Dengue Vaccine in 2025, Prioritizing Those Previously Infected
Table of Contents
San luis, Argentina – In a proactive move to combat the spread of dengue fever, the San Luis Ministry of Health announced plans to implement the Qdenga vaccine starting in mid-January 2025. The initial rollout will prioritize healthcare workers and individuals who contracted dengue during the 2023-2024 season.
Over 3,000 patients are expected to receive the first dose of the vaccine,which is recommended by the World Health Institution (WHO) for individuals aged 5 to 60 who have previously had dengue.
“This vaccine is a crucial tool in our fight against dengue,” said Dr. Maria rodriguez, Director of Epidemiology at the San Luis Ministry of Health. “By focusing on those who have already experienced the disease, we aim to substantially reduce the risk of severe complications and future outbreaks.”
Who Will Receive the vaccine?
The vaccination program will target:
Individuals registered as dengue-positive cases in the SISA system during the 2023-2024 season.
Individuals who can provide medical certification and laboratory results confirming a dengue diagnosis. Patients who have already received one dose and are eligible for a second dose booster.
Who is Not Eligible?
The vaccine is not recommended for:
Individuals under 5 years old or over 60 years old.
People with congenital or acquired immunodeficiency, HIV infection, pregnant women, or breastfeeding mothers due to the vaccine containing a live virus. Individuals with hypersensitivity to the vaccine’s active ingredients or excipients from a previous dose.
How Will the Vaccination Process Work?
The Ministry of Health will contact eligible patients registered in the SISA system via text message, providing details about the date, time, and location for vaccination. The vaccine will be administered free of charge at designated vaccination centers.
Individuals not registered in the SISA system can receive the vaccine by presenting a medical certificate and laboratory results confirming a dengue infection.
Importance of Vaccination
Dengue fever is a mosquito-borne viral infection that can cause a range of symptoms, from mild fever and headache to severe complications like dengue hemorrhagic fever.
The qdenga vaccine has shown high efficacy in preventing dengue in individuals who have previously been infected.By vaccinating those most at risk, San Luis aims to reduce the burden of dengue on its healthcare system and protect its citizens from this potentially deadly disease.
San Luis Prepares for Dengue Vaccine Rollout in 2025
San Luis, Arizona – As the threat of dengue fever looms large, San Luis residents are gearing up for a vaccination campaign set to begin in mid-January 2025. The vaccine, recommended by the World Health Organization for individuals aged 5 to 60 who have previously contracted dengue, aims to curb the spread of this potentially deadly mosquito-borne illness.
“They said mid-January 2025, which seems like ages away!” exclaimed Sofia, a San Luis resident, discussing the upcoming vaccination drive with her friend Miguel.
The city was hit hard by dengue during the recent season, with over 3,000 cases reported in the 5 to 59 age group.While many experience mild symptoms, dengue can lead to severe complications, even death, notably upon reinfection.
“Apparently, the vaccine is only for people who already had dengue,” Sofia explained.”They mentioned something about getting really sick if you get it again.”
Miguel, like many others, was unaware of the potential dangers of a second dengue infection. “That’s scary. I didn’t realize it could be so risky the second time,” he admitted.
Health officials are prioritizing healthcare workers and those who contracted dengue during the last season for the initial phase of the vaccination program.
Individuals who are not part of the SISA system, which tracks dengue cases, will need to provide a doctor’s note and lab results confirming a previous dengue infection to be eligible for vaccination.While the vaccine offers hope for mitigating the impact of dengue, it is not a universal solution. Young children, older adults, and pregnant women are currently ineligible for the vaccine.
“Hopefully, this helps to stop dengue from spreading so much,” Miguel said, expressing optimism about the vaccination campaign.
Sofia agreed,adding,”It’s been a real problem lately.”
As san Luis prepares for the rollout of the dengue vaccine, residents are hopeful that this crucial step will help protect the community from the threat of this debilitating disease.
San Luis Takes Aim at Dengue with 2025 Vaccine Rollout
San Luis, Argentina – In a move to protect its citizens from the debilitating dengue fever, the San Luis Ministry of Health has announced an innovative vaccination program set to begin in mid-January 2025. This program will prioritize those who have already battled the virus, offering them crucial protection against future outbreaks.
Qdenga Vaccine: A Proactive Approach
The Qdenga vaccine, recommended by the World Health Organization (WHO) for individuals aged 5 to 60 who have previously contracted dengue, is the cornerstone of this program. Over 3,000 residents are expected to receive the first dose, marking a meaningful step in mitigating the risk of severe complications and preventing the spread of the disease.
Exclusive Interview
We recently sat down with Dr. Maria Rodriguez, Director of Epidemiology at the San Luis Ministry of Health, to discuss the rationale and impact of this vaccination program.
“This vaccine is a crucial tool in our fight against dengue,” Dr. Rodriguez explained. “By focusing on those who have already experienced the disease, we aim to substantially reduce the risk of severe complications and future outbreaks.”
Who is Eligible?
The initial phase of the vaccination program will target:
- Individuals registered as dengue-positive cases in the SISA system during the 2023-2024 season.
- Individuals who can provide medical certification and laboratory results confirming a dengue diagnosis.
- Patients who have already received one dose and are eligible for a second dose booster.
Who is Not Eligible?
It’s vital to note that the vaccine is not recommended for:
- Individuals under 5 years old or over 60 years old.
- People with congenital or acquired immunodeficiency, HIV infection, pregnant women, or breastfeeding mothers due to the vaccine containing a live virus.
- Individuals with hypersensitivity to the vaccine’s active ingredients or excipients.
Utilizing the Qdenga vaccine in this strategic manner demonstrates San Luis’s commitment to safeguarding its population’s health. The program’s success hinges on the participation of eligible residents, emphasizing the importance of individual duty in fighting this persistent public health challenge.